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Abstract: Primary congenital glaucoma (PCG) is a heterogeneous, inherited, and severe optical
neuropathy caused by apoptotic degeneration of the retinal ganglion cell layer. Whole-exome sequencing
analysis of one PCG family identified two affected siblings who carried a low-frequency homozygous
nonsense GUCA1C variant (c.52G > T/p.Glu18Ter/rs143174402). This gene encodes GCAP3, a member of
the guanylate cyclase activating protein family, involved in phototransduction and with a potential role in
intraocular pressure regulation. Segregation analysis supported the notion that the variant was coinherited
with the disease in an autosomal recessive fashion. GCAP3 was detected immunohistochemically
in the adult human ocular ciliary epithelium and retina. To evaluate the ocular effect of GUCA1C
loss-of-function, a guca1c knockout zebrafish line was generated by CRISPR/Cas9 genome editing.
Immunohistochemistry demonstrated the presence of GCAP3 in the non-pigmented ciliary epithelium
and retina of adult wild-type fishes. Knockout animals presented up-regulation of the glial fibrillary
acidic protein in Müller cells and evidence of retinal ganglion cell apoptosis, indicating the existence
of gliosis and glaucoma-like retinal damage. In summary, our data provide evidence for the role of
GUCA1C as a candidate gene in PCG and offer new insights into the function of this gene in the ocular
anterior segment and the retina.
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1. Introduction
Glaucoma is a heterogeneous group of progressive and irreversible optic neuropathies stemming from
the apoptotic death of retinal ganglion cells. It results in characteristic visual field loss. Common glaucoma
types have an adult onset, though infrequent early onset forms of glaucoma are also a significant
cause of visual disability. Glaucoma that occurs before three years of age and associates with isolated
trabeculodysgenesis is called primary congenital glaucoma (PCG) [1]. Arrested maturation of tissues
derived from cranial neural crest cells is believed to underlie this disease. This alteration results in
increased aqueous humor (AH) outflow resistance, elevated intraocular pressure (IOP), and optic nerve
degeneration and usually manifests in the form of the classic triad of tearing, photophobia and corneal
clouding. PCG affects one in 10,000–20,000 live births in Western countries [2], with an increased incidence
in consanguineous populations [3,4]. Although PCG has a poorly understood pathogenesis, it has a strong
genetic component and is frequently inherited as an autosomal-recessive trait with incomplete penetrance
(ranging from 40% to 100% [5]) and variable expressivity. The first identified and most prevalent cause
of this type of inheritance is loss-of-function (LoF) of the CYP1B1 (CYTOCHROME P450, SUBFAMILY I,
POLYPEPTIDE 1, MIM# 601771) gene [5], which is present in 18–48% of non-consanguineous European
patients [6,7]. Our previous studies showed that approximately one-third of Spanish PCG patients
carry CYP1B1 pathogenic genotypes [8,9]. Several other disrupted genes have also been identified
in this disease, illustrating the genetic heterogeneity of PCG. LoF of the LATENT TRANSFORMING
GROWTH FACTOR-β-BINDING PROTEIN 2(LTBP2, MIM# 602091) gene results in occurrence of the
disease in a reduced percentage of patients [10–12]. Rare variants in the angiopoietin receptor TEK (TEK,
MIM# 600221) likely underlie dominant PCG with variable expressivity in some patients [13]. Additionally,
rare hypermorphic G-PATCH DOMAIN-CONTAINING PROTEIN 3 (GPATCH3, MIM# 617486) variants
have been reported in some cases [14]. The presence of disease-causing variants in other genes such as
MYOCILIN (MYOC, MIM# 601652) [15,16] and FORKHEAD BOX C1 (FOXC1, MIM# 601090) [17,18] and
CPAMD8 [19,20] have also been described in a few patients.
Herein, we extend our previous family-based whole-exome sequencing (WES) study to identify
PCG-causing variants in 26 non-related probands. We identified the presence of one low-frequency
homozygous nonsense GUCA1C variant in two siblings, inherited in a recessive fashion. The role
of GUCA1C in the disease was also evaluated by expression analyses in ocular human tissues and
functional studies in zebrafish. Our data offer novel insights into the genetics of this disease and the
functional role of GUCA1C in the ocular anterior segment and the retina.
2. Materials and Methods
2.1. Subjects
The family reported in this study belong to a cohort of 26 PCG previously analyzed by whole-exome
sequencing [14]. Glaucoma specialists carried out the clinical examination of the patient and PCG
diagnosis was performed as previously described [9]. The human study and informed consent
procedures were approved by the Ethics Committee for Human Research of the Hospital Clínico San
Carlos (approval number 13/388-E). The research followed the tenets of the Declaration of Helsinki.
Informed written consents were obtained prior to participants’ inclusion in the study.
2.2. Human Tissue Samples
A human eye from a 45-year-old Caucasian female donor (cadaver) with no reported ocular
pathology was obtained within 24 h after enucleation from the USA National Disease Research
Interchange. The eye was microdissected from the posterior pole and the vitreous and aqueous humor
were collected. Then, the eye was fixed with 4% paraformaldehyde in 0.1 phosphate buffer (pH 7.2)
and embedded in paraffin as previously reported [21]. Histological microtome Sections (10 µm) were
deparaffinized for immunohistochemical analysis.
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2.3. Animals
Wild-type AB zebrafish (Danio rerio) were maintained at 28 ◦C with a 14 h on/10 h off light cycle
and were fed a standard diet according to established protocols [22]. Zebrafish embryos were raised
at 28 ◦C in E3 medium (5 mM NaCl; 0.17 mM KCl; 0.33 mM CaCl2; 0.33 mM MgSO4, and 0.0001%
methylene blue, pH 7.2). All animal husbandry and experiments were approved and conducted
in accordance with the guidelines set forth by the Institutional Animal Research Committee of the
University of Castilla-La Mancha (approval number PR-2015-04-10).
2.4. Next Generation Sequencing (NGS)
Genomic DNA was extracted from the subjects’ peripheral blood, using the QIAamp DNA
Blood Mini Kit (Quiagen, Hilden, Germany) and processed for NGS as previously described [14].
Candidate disease-causing variants were identified through the application of a multistep filtering
approach. Initially, common variants, defined as those with a minor allele frequency higher than
1% in the Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/) or gnomAD
(https://gnomad.broadinstitute.org/) databases and with a genotype quality lower than 50 reads were
filtered out. Next, LoF variants (nonsense, indels producing a frameshift and variants affecting
canonical splicing sites) were selected. Finally, to identify potential recessive genotypes, we selected
variants in compound heterozygosis or homozygosis. The candidate variant identified by NGS was
confirmed and segregated in the family by Sanger sequencing.
2.5. Quantitative Reverse Transcription PCR (qRT-PCR)
RNA was isolated from pools of 50 zebrafish larvae (6 dpf) using the RNeasy Minikit
(Qiagen #74104) and treated with RNase-free DNase I according to the manufacturer’s
instructions. Purified RNA was used for cDNA synthesis using RevertAid First Strand
cDNA Synthesis Kits (Thermo Scientific #K1622). The expression of guca1c mRNA relative
to ef1αmRNA was determined by the 2−∆∆Ct method [23] using the following primer
pairs, respectively: guca1cE2FW, 5′-ACGGCAAGATCGACAGAGATGAAATG-3′/guca1cE2Rv,
5′-CCTCTCATAGATCAGGCTCACG-3′ and ef1αFw, 5′-CTGGAGGCCAGCTCAAACAT-3′/ef1αRv,
5′-ATCAAGAAGAGTAGTACCG CTAGCATTAC-3′. PCR analysis was carried out with cDNA as
a template in a reaction volume of 10 µL containing 5 µL of Power SYBR Green PCR Master Mix
(Thermo Fisher Scientific, Waltham, MA, USA) and 200 nM of each primer. Thermocycling included
an initial denaturation step at 95 ◦C for 10 min, followed by 40 cycles consisting of 15 s denaturation
at 95 ◦C for 60 s and a combined annealing and extension step at 60◦ C for 40 s. DNA amplifications
were carried out in an ABI PRISM 7500 Fast real-time PCR system (Life Technologies, Foster City,
CA, USA). Template cDNA was omitted in the qRT-PCR negative control. qRT-PCR results from
at least three independent experiments carried out in triplicate were used for calculation of mean
expression values in each sample.
2.6. Western Blotting and Antibodies
For western blot analysis of GCAP3 in guca1c KO zebrafish, eight embryos (6 dpf) per guca1c
genotype (mutant homozygote, heterozygote and wild-type) were lysed, and 60 µg of total protein
were fractionated by SDS-PAGE using the Mini-PROTEAN III Gel Electrophoresis System (BIORAD,
Hercules, CA, USA). Then, proteins were transferred onto Hybond ECL nitrocellulose membranes
(Amersham, Arlington Heights, IL, USA) as previously described [24]. GCAP3 was detected using a
commercial rabbit polyclonal primary antibody (anti-human GUCA1C, HPA041597, Sigma-Aldrich,
St. Louis, MO, USA) (1:50). Horseradish peroxidase-conjugated anti-rabbit IgG (#1858415, Pierce) was
uses as a secondary antibody (1:1000). Chemiluminescence detection was performed as previously
described [24].
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2.7. Light Microscopy
Zebrafish tissue samples employed for light microscopy were immediately fixed in 2.5%
glutaraldehyde/4% paraformaldehyde in 0.1 M Millonig’s phosphate buffer (PBM, pH 7.4), for 4 h
at 4 ◦C, washed in PBM and dehydrated in ascending grades of acetone (30–100%) and embedded
in araldite resin. Semi-thin Sections (0.5 µm) were stained with toluidine blue and analyzed by
light microscopy.
2.8. Fluorescence Immunohistochemistry (FIHC)
Paraffin-embedded human eye Sections (10 µm) were obtained with a RM 2135 BioCut Rotary
Microtome (Leica Ltd., Wetzlar, Germany). Zebrafish embryos (96 hpf) and heads of both adult
(6 months) wild-type and knockout (KO) guca1c zebrafish were fixed in 4% paraformaldehyde
overnight and cryoprotected in 30% sucrose/0.1 M DPBS for two days at 4 ◦C. Thereafter, the samples
were embedded and oriented in 10% porcine gelatin with 15% sucrose and stored at −80 ◦C.
Cryosections (10–14µm) were obtained in a Leica CM3050 S cryostat and stored at−80 ◦C. Tissue sections
were blocked in blocking solution [10% fetal bovine serum (FBS), 1% DMSO and 1% Triton X-100 in
DPBS] at room temperature for 1 h. Thereafter, sections were incubated with primary antibodies at
optimal dilution [rabbit anti-GCAP3 (1:200) (HPA041597, Sigma) or mouse anti-GFAP (1:50) (sc-33673,
Santa Cruz Biotechnology, Santa. Cruz, CA, USA)] overnight at 4 ◦C. Then, after wash, sections were
incubated with the corresponding secondary antibody: Cy2 donkey anti-rabbit (1:1000) (Jackson
ImmunoResearch, West Grove, PA, USA) or Cy2 donkey anti-mouse (1:1000) (Jackson ImmunoResearch).
All tissue sections were counterstained with DAPI (D8417, Sigma-Aldrich) for nuclear staining,
mounted in Fluoroshield Medium (F6182, Sigma-Aldrich) and visualized using a LSM710 confocal
microscope (Carl Zeiss, Jena, Germany). Fluorescence emitted by DAPI, the Cy2-conjugated antibody
and embryo autofluorescence was registered at the following wavelengths, respectively: 411–464 nm,
490–518 nm and 553–677 nm. Negative controls were made omitting the primary antibodies.
Apoptotic cell death was evaluated by Terminal dUTP Nick-End Labeling (TUNEL) assay using the
In-Situ Cell Death Detection Kit, Fluorescein (11684795910, Roche, Diagnostics, Mannheim, Germany),
following the manufacturer’s instructions. As a positive control, tissue sections of wild-type zebrafish
were incubated for two min with permeation solution (0.1% Tritón-X100, 0.1% sodium citrate) followed
by incubation with DNase I solution (3 U/mL DNase, 50 mM Tris-HCl pH 7.5, 1 mg/mL FBS) for
10 min. DNase I treatment was omitted in the negative controls. Samples were stained with DAPI for
nuclear staining, mounted in DAKO Fluorescent Mounting Medium and examined under an Eclipse
Ti microscope (Nikon, Tokyo, Japan). For both GGAP immunodetection and TUNEL, three random
fields per tissue section were examined by a single masked observer. Two tissue sections/eye were
employed for each technique.
2.9. CRISPR/Cas9 Gene Editing
Target selection and sgRNA design were performed using the Custom Alt-R CRISPR-Cas9 guide
RNA (https://eu.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM) and CHOPCHOP V.3
programs (http://chopchop.cbu.uib.no). Potential off-target sites and highest on-target activity of
sgRNAs common to both programs were assessed with CRISPR-Cas9 guide RNA design checker (https:
//eu.idtdna.com/site/order/designtool/index/CRISPR_SEQUENCE). To disrupt the guca1c gene, a pair
of crRNAs (36 ng/µL each) targeting exon 1 (guca1cE1g1, 5′-GGAGATGCA GGGCATGACGG-3′ and
guca1cE1g2, 5′-GGAGGAGGCCAGCAGCTACG-3′) and tracrRNA (67 ng/µL) were mixed, incubated
for 5 min at 95 ◦C and cooled at room temperature. The crRNAs/tracrRNA complexes were mixed with
the Cas9 protein (250 ng/µL) and incubated for 10 min at 37 ◦C to form the ribonucleoprotein (RNP)
complex. The RNP complexes were injected (3 nL) into the animal pole of one-cell stage embryos
(50–250 embryos/experiment) using a Femtojet 5247 microinjector (Eppendorf, Hamburg, Germany)
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under a Nikon DS-Ri2 stereomicroscope. All reagents for CRISPR/Cas9 gene editing were provided by
Integrated DNA Technologies, Inc. (Coralville, IA, USA).
2.10. Zebrafish DNA Extraction
Adult fishes were anesthetized with 0.04% tricaine methanesulfonate (MS222) and euthanized
by prolonged immersion in MS222 (200–300 mg/L). Larvae were treated with 0.02% MS222.
PCR-ready genomic DNA was isolated from whole zebrafish embryos (24 hpf) and from the caudal fin
of anesthetized larvae (6 dpf) or adult zebrafish using the HotSHOT method [25]. Briefly, tissue samples
were incubated with 20 µL of base solution (25 mM KOH, 0.2 mM EDTA) at 95 ◦C for 30 min in a
thermal cycler C100 (BIORAD, Hercules, CA, USA), then 20 µL of neutralization buffer (40 mM TrisHCl,
pH 5) were added.
2.11. Genotyping by High-Resolution Melting (HRM)
For HRM genotyping the PCR reactions (10 µL total volume) were prepared using 5 µL of
MeldtDoctor HRM Master Mix (#4415440, Thermo Fisher Scientific), 1.5 µL (3 µM) of each primer
(guca1cHRMFw, 5′-GTCAGGCTTGATTAGCGTGTTC-3′; guca1cHRMRv, 5′-AAACTCATTTATTGC
GCGTGTT-3′) and genomic DNA (2 µL). The PCR was performed in a 7500 Fast real-time PCR system
thermal cycler (Thermo-Fisher Scientific). Thermocycling included an initial denaturation step at 95 ◦C
for 10 min, followed by 40 cycles consisting of 15 s denaturation at 95 ◦C and a combined annealing
and extension step at 60 ◦C for 60 s. The melt curve stage consisted of the following steps: denaturation
at 95 ◦C for 10 s, annealing at 60 ◦C for 60 s, HRM at 95 ◦C for 15 s and a final step of annealing at 60 ◦C
for 15 s. The raw melting curve data were processed by the High-Resolution Melt Software v. 3.0.1
(Thermo-Fisher Scientific).
2.12. Characterization of the CRISPR/Cas9-Induced Mutation
To characterize the KO mutation, DNA samples were analyzed by Sanger sequencing using
the following primers: guca1cSeqFw, 5′-GCAGCGGCAGACTCTTCACATCTCG-3′; guca1cSeqRv,
5′-TAGTGGAGCTCTAAAACCTGAAATGAATGGG-3′.
2.13. Statistics
Statistical comparisons between groups were performed using either the t-test or the one-way
ANOVA using the SigmaStat 2.0 software (Systat Software Inc., San Jose, CA, USA).
3. Results
3.1. Identification of Rare GUCA1C Variants by WES
This study is an extension of our previous WES analysis of 26 severe PCG cases diagnosed before
the fourth month of life, that were ruled out as carrying CYP1B1 alterations, and for which we reported
no shared disease-causing genetic alterations [14]. Herein, we focus on the identification of genetic
alterations underlying PCG in a family with two affected siblings (PCG-94). To that end, we designed
a variant filtering algorithm aimed at identifying rare coding variants with predicted moderate or high
functional impact (frameshift, nonsense, missense, and donor/acceptor splicing sites) with recessive
inheritance (variants in homozygosis or compound heterozygosis) and shared by the two PCG siblings.
This filtering pipeline identified only one homozygous nucleotide substitution in the GUCA1C gene
(c.52G > T), predicted to result in a nonsense variant (p.(Glu18Ter), Figure 1A) that likely leads to
the complete LoF of the gene product. This variant is reported in the gnomAD v2.1.1 database with
low frequency (0.004513) and with three homozygous genotypes. The segregation of the variant was
confirmed by Sanger sequencing (Figure 1B,C).
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3.2. Clinical Features of Patients with the Nonsense GUCA1C Variant
The proband was diagnosed with bilateral congenital glaucoma at birth in a different Hospital and
currently he is 48 years old. He attended the Ophthalmology Department of San Carlos Hospital with
endophthalmitis at the age of 28 years. The patient presents with amaurosis in the right eye and light
perception in the left eye (LE), bilateral severe optic nerve excavation and an IOP value of 17 mmHg in
the LE with (Table 1). The patient was subjected to several bilateral glaucoma operations and requires
two drugs (brimonidine tartrate and timolol) to control the IOP in the LE. Ocular examination also
revealed bilateral megalocornea, Haab’s striae and leukoma, as well as band keratopathy in the left eye
(Table 1). Additional ophthalmological features are presented in Table 1.
Table 1. Ophthalmological features of the index case with GUCA1C variants (PCG-94).
Patient II-3
Age at diagnosis/age at last ophthalmic revision Birth/48 years
IOP at diagnosis (mm Hg) (RE/LE) NA
Last IOP (mm Hg) (RE/LE) NA/17
Last cup/disc ratio (RE/LE) 0.9-1/0.9-1
Number and type of glaucoma surgery (RE/LE) 6 (3G, 3T)/5 (3G, 2T)
Number of antiglaucoma drugs (RE/LE) 0/2, brimonidine tartrate and timolol
Visual acuity (RE/LE) Amaurosis/Light perception
Lens Cataract (B)
Central corneal thickness (m) (RE/LE) 740/740
Corneal morphology MC (B), HS (B), L (B), BK and SE (RE)
B: bilateral; BK: band keratopathy; G: goniotomy; HS: Haab’s striae; IOP: intraocular pressure; LE: left eye; MC:
megalocornea; NA: not available; RE: right eye; L: leukoma; SE: stromal edema; T: trabeculectomy.
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The patient’s siter was 36 years old at the time of the study and was diagnosed with unilateral
congenital glaucoma in a different hospital. Additional clinical information was not available.
3.3. Expression of GCAP3 in Adult Human Ocular Tissues
To the best of our knowledge the presence of the GCAP3 protein in adult human ocular anterior
segment tissues has not been studied. FIHC using a commercial anti-human GUCA1C antibody
showed labeling of the ciliary body with intense cytoplasmatic immunoreactivity in the non-pigmented
ciliary epithelium (NPCE) and immunostaining of ciliary muscle longitudinal fibers (Figure 2A,B).
No positive immunolabeling was detected in the trabecular meshwork (Figure 2C). The iris sphincter
muscle was highly positive for GCAP3 (Figure 2D). Some iris stroma cells, probably fibroblasts,
also showed the presence of immunoreactivity for this protein (Figure 2D). The anti-GUCA1C antibody
also labeled cells of the corneal epithelium, keratocytes, and especially the corneal endothelium
(Figure 2E,F). As expected, the retina was also positive for GCAP3, photoreceptors (both rods and
cones) were immunoreactive against GCAP3 with strong signals in the inner and outer segments
(Figure 2G,H). Some cells in the retinal ganglion layer showed a diffuse immunostaining (Figure 2I).
The specificity of these signals was supported by their absence in the corresponding negative controls
(Figure S1). These results clearly show the expression of GCAP3 in the tissues of the ocular anterior
segment involved in the production and exit of the aqueous humor, suggesting, along with previous
studies [26,27], that this protein plays a role in IOP homeostasis and that its functional disruption may
contribute to glaucoma.
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Figure 2. Detection of GCAP3 in human ocular tissues by confocal fluorescence immunohistochemistry;
histological Sections (10 µm) of a human eye from a 45-year-old Caucasian female donor were incubated
with rabbit anti-human GUCA1C primary antibody (1:200) and donkey Cy2-anti-rabbit secondary
antibody (1:1000); (A) Confocal wide-field micrographs of ciliary processes; (B) Ciliary muscle;
(C) Trabecular meshwork; (D) Iris; (E) Corneal epithelium; (F) Corneal endothelium and (G) Retina.
(H,I) detailed images of photoreceptors and the ganglion cell layer, respectively. Both rods (yellow
arrowheads) and cones (yellow arrows) showed positive GCAP3 immunoreactivity (H). Green, blue and
red signals correspond to GCAP3 immunoreactivity, DAPI nuclear staining and tissue autofluorescence,
resp ctively. BM: Bowman’s membrane. CEN: rneal endothelium. CEP: Corneal Epithelium. CS:
Corneal stroma. CPS: Ciliary process stroma. DM: Descemet’s membrane. GC: Gangli n cells. I: Iris.
INL: Inne nuclear layer. IPL: Inner plex form layer. IPE: Iri igm nted epithelium. IS: Iris stroma.
ISM: Iris sphi cter muscle. K: Keratocyte. LF: Longitudinal fibers. NFL: Nerve fiber layer. NPCE:
Non-pigmented ciliary epithelium. ONL: Outer nuclear layer. OPL: Outer plexiform layer. PCE:
Pigmented ciliary epithelium. POS: Photoreceptor outer segments. SC: Schlemm’s canal. The negative
controls are shown in Figure S1.
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3.4. Functional Analysis of guca1c in Zebrafish
To further evaluate the role of GUCA1C LoF in congenital glaucoma and retinal physiology,
we used zebrafish as an animal model. The human GUCA1C gene is composed of four exons and
is located on chromosome 3. Two orthologous genes—guca1c and guca1d—have been identified
in the zebrafish genome on chromosomes 15 and 21, respectively. Both genes emerged via a gene
duplication event from an ancestral gene common to other teleost fishes [28]. Moreover, the expression
pattern for both guca1c and guca1d genes in zebrafish larvae is described as being very similar [29,30].
Because there is no evidence of functional divergence among these genes, we prioritized guca1c LoF
analysis in our study, although possible compensatory phenotypic effects by guca1d on a guca1c KO
background cannot be disregarded. DNA sequence comparison analyses of the human and zebrafish
GUCA1C genes show similar overall intron-exon organization (Figure 3A) and the corresponding
GCAP3 proteins present conserved EF-hand calcium-binding domains (Figure 3B) and 44% amino
acid identity (Figure 3C).
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green boxes. Black line: Peptide used as an antigen to obtain the commercial anti-CGAP3 antibody 
used in this study; (C) Amino acid sequence alignment of human and zebrafish GCAP3 proteins. The 
alignment was carried out with ClustalW14 (https://www.ebi.ac.uk/Tools/msa/clustalo/) [31]. The 
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To ensure disruption of the zebrafish guca1c gene and to facilitate the identification of F0 mutants 
by HRM, we used simultaneously two overlapping crRNAs targeting exon1 (Figures 3A and 4A). 
The RNP complexes (crRNAs/tracrRNA and Cas9 protein) were co-injected into the animal pole of 
AB zebrafish at the one-cell stage of development (Figure 4B). The injected embryos (F0) were raised 
Figure 3. S ructural conservation of human GUCA1C and its ortholog zebrafish gene and
protein. (A) Genomic alignment of human GUCA1C (ENSG00000138472) and zebrafish guca1c
(ENSDARG 030758) genes. The dotted gray lines show the co respondence of conserved exons.
The black a ro s indicate the sense of transcription. The blue a rows indicate the localization of the
crRNAs used in thi study. The “Ensembl region comparison tool” wa used to obtain this image.
E: Exon; (B) Human and zebrafish GCAP3 protein domain conservation (ENST 0261047.8 and
ENSDAR 00 . , respectively). Domains are indicated according to the Prosite database (https:
//prosite.expasy.org/). The numbers corre p nd to amin cid positions. EF: EF-hand calcium-binding
domain. Pink boxes: Calcium-binding sites. Nonfunctional EF-ha ds are indicated by light green boxes.
Black line: Peptide used as an antig n to obtain the commercial anti-CGAP3 antibody used in this study;
(C) Amino aci sequence alignment of human and zebrafish GCAP3 proteins. The alignment was
carried out with ClustalW14 (https://www.ebi.ac.uk/Tools/msa/clustalo/) [31]. The asterisks indicate the
positions where all the amino acids are identical. Two vertical dots show amino acids with si ilar
chemical properties. One dot denotes amino acid positions with weak chemical similarity. Pink boxes:
Calcium-binding sites.
To ensure disruption of the zebrafish guca1c gene and to facilitate the identification of F0 mutants
by HRM, we used simultaneously two overlapping crRNAs targeting exon1 (Figures 3A and 4A).
The RNP complexes (crRNAs/tracrRNA and Cas9 protein) were co-injected into the animal pole of AB
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zebrafish at the one-cell stage of development (Figure 4B). The injected embryos (F0) were raised to
adulthood and screened by HRM for the presence of germ-line transmitted guca1c mutations (Figure 4B).
F0 mutant mosaic fishes were outcrossed with wild-type animals and the offspring (F1) was screened for
guca1c mutations by HRM. Several fishes were identified as transmitting mutations; Sanger sequencing
identified one animal harboring an indel variant (c. 140_141insGG,155-166delinsGTCCAGGTCCAGGT,
NM_194393) (Figure 4C). It was predicted that this mutation would result in a frameshift and a premature
termination codon (PTC) in the new open reading frame (p.(Thr47Argfs*63, NP_919374)) (Figure 4C).
This individual was selected to establish the null guca1c zebrafish line. Mutant F1 heterozygotes were
backcrossed with wild-type AB zebrafish to produce the F2 offspring. The F3 progeny was obtained
by inbreeding F2 heterozygotes (Figure 4B); homozygous mutant guca1c fishes were identified by
Sanger sequencing.
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mutant larvae (6 dpf) were less than 40% of the value determined in their wild-type littermates
(Figure 5A), in accordance with our hypothesis. On the other hand, if the residual mutant mRNA was
translated, it would result in a truncated and likely, null protein because it would lack most of the
functional domains of the normal protein. Western blot analysis of GCAP3 in wild-type zebrafish
larvae (6 dpf) using the same commercial antibody as that used for the immunohistochemistry of
human tissues showed a specific doublet higher than 45 kDa (Figure 5B), which, in accordance with
previous reports, may correspond to a dimer of the protein [32]. As expected, the intensity of this signal
in homozygous mutant larvae was undetectable and reduced in heterozygous larvae. Parallel control
western blot analyses of beta-actin showed no significant differences in sample loading. Altogether,
these results support a guca1c LoF in the generated zebrafish line.
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Figure 5. olecular characterization of the guca1c KO zebrafish line. (A) qPCR of guca1c mRNA levels in
pools of 50 zebrafish larvae (6 dpf). The results are expressed as relative expression levels normalized to
wild-type. Asterisks indicate statistical significance compared to the control: p < 0.001 (***); (B) Western
immunoblot analysis of GCAP3 in zebrafish larvae (6 dpf). Western blotting was carried out ith
protein extracts (75 µg total protein) obtained from pools of eight larvae (6 dpf). GCAP3 was detected
using an anti-GUCA1C primary antibody (1:50) (left panel). As a loading control, the membrane was
stripped and incu ated with an anti-β- ctin anti ody (1:500) (bottom p nel); replica of the membrane
was analyzed in parallel with the second ry goat anti-r bbit HRP antibody (1:1000) as a negative control
(right panel). The arrowhead indicates a positiv double band over 50 KDa, which may correspo
to a GCAP3 dimer. MWM: Molecular weight mark . +/+: Wild-type; +/-: KO heterozygote; -/ :
KO homozygote.
3.5. Phenotypic Characterization of guca1c KO Zebrafish
No significant gross external macroscopic alterations were observed in either larvae (96 hpf) or adult
(6 months) guca1c KO fishes. Immunohistochemical analysis of GCAP3 in adult (6 months) wild-type
and KO zebrafish eyes revealed immunopositive signals in the non-pigmented epithelium of the
ciliary zone (Figure 6A,D), which is involved in aqueous inflow. Additional GCAP3 immunoreactivity
was observed in the corneal epithelium (Figure 6G) and weak signals were observed in keratocytes
(Figure 6G, arrows). The GCAP3 immunoreactivity in the non-pigmented epithelium and keratocytes
was absent in the KO animals (Figure 6B,E,H). Nevertheless, the positive labeling remained in the
corneal epithelium of KO zebrafishes, indicating a possible antibody cross-reaction with other GCAPS
(Figure 6H). The absence of immunoreactivity in the negative controls indicated the specificity of the
primary antibody (Figure 6C,F,I).
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The images are repr sentative of the results obs rved in three fishes of each genotype. c: Cornea; al:
Annular ligament; cz: Cili ry zo e; pe: Ciliary pigmented epith lium; npe: Non-pigmented ciliary
e ithelium; ce: Corneal epithel um; cs: Corneal stroma.
I unohistochemistry of the wild-type retina detected GCAP3 immunoreactivity in photoreceptors
(rods and cones) (Figure 7A, blue and white arrowheads, respectively), inner and outer plexiform layers
(Figure 7A, arrows) and ganglion cell layer (Figure 7A, empty arrow). These immunosignals were absent
in the KO retina and the negative control, demonstrating their specificity (Figure 7B,C, respectively).
No gross structural alterations were observed in the retina of KO zebrafish using this technique.
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In accordance ith the previous result, histological analysis of toluidine-blue-stained tissue
sections did not revealed any gross structural retinal alteration in the KO zebrafish (Figure S2 ,B),
ho ever, it did sho thinning of the KO corneal epithelium (5.1 ± 0.2 µm) compared to that of
wild-type animals (8.6 ± 0.2 µm) (Figure S2C,D).
ext, e evaluated retinal injury in the KO animals by i munohistochemistry. To that end,
we selected two wild type and two KO zebrafish. First, we used an antibody raised against the glial
fibrillary acidic protein (GFAP). No detectable im unoreactivity was observed in the retina of wild-type
animals (Figure 8A); however, a significant upregulation of this protein was present in Müller cells of
KO retinas, indicating the existence of gliosis associated to GCAP3 deficiency (Figure 8B, arrowheads).
GFAP immunoreactive cells were observed bilaterally in the two fishes, with an average number of
14 positive cells per microscopic field in the ganglion cell layer. The absence of immunoreactivity in
the negative control, carried out with only the secondary antibody, indicated the specificity of the
primary antibody (Figure 8C). In addition, analysis of retinal apoptosis by TUNEL assay showed the
absence of labeling in the retina of wild-type animals (Figure 8D) hile revealed some positive nuclear
signals in the ganglion cell layer of KO animals (Figure 8E,F, arrows). Apoptotic cells were detected
bilaterally in one KO fish and unilaterally in the second animal analyzed (three positive cells were
observed in total). The presence of nuclear staining in different retinal layers (particularly ganglion
and outer nuclear cells) of the positive control (Figure 8G, arrows), along with the absence of positive
cells in the negative control (Figure 8H), supported the specificity of the signals.
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wild-type; -/-: guca1c KO. The images are representative of the results observed in two fishes of each 
genotype. Two tissue sections per eye were analyzed. 
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addition, these features made unlikely the existence of disease-associated de novo variants. Whole-
exome sequencing revealed the presence of one homozygous nonsense GUCA1C variant in the two 
affected siblings that segregated with the disease following the expected autosomal recessive 
inheritance. We also applied filters to identity rare compound heterozygous variants carried by the 
two affected siblings, with a high and moderate predicted functional effect, but we did not identify 
any variant of this type. The GUANYLATE CYCLASE ACTIVATOR 1C (GUCA1C) gene encodes the 
guanylate cyclase 3 activating protein (GCAP3), a calcium-binding protein that belongs to the 
calmodulin gene superfamily [33]. This protein is composed of 209 amino acids (23.8 kD) and presents 
57% and 49% amino acid similarity with GCAP1 and GCAP2, respectively. Like other GUCAs, 
GCAP3 contains a putative N-myristoylation site at Gly 2 and three putative EF-hand motifs involved 
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(A,B) Immunolabeling against GFAP (green) was used to analyse glial activation in histological
Sections (10 µm) of zebrafish eyes incubated with either a rabbit anti-GFAP primary antibody (1:50)
and a donkey Cy2-anti-rabbit secondary antibody (1:1000). GFAP labelling of Müller c lls (green
signal) was absent in wild-type zebrafish (A) and prese t in the KO animals (B, a ro hea s),
i li ri ti i i t ti c t l; ( ,H) Apoptosis wa
assessed u ing terminal dUTP nick-e d labeling (TUNEL) of fragmented DNA; ( ) TUNEL-positive
cells were not d t cted in he reti a of wild-type zebrafish; (E and F) TUNEL-positive retinal ganglion
cells were ob erved in two independe t microscopic fields f the KO zebrafish (arrows); (G,H) Retinal
sections of adult zebra fish incubated with DNase I or with only the labeling solution were used as
a positive and negative co trols, respectively. Note the presence of positive cells in different retinal
layers (arrows); Microphotographs in panels (D–H) were obtained using a Nikon Eclipse Ti microscope.
Blue and red signals correspond to DAPI nuclear staining and tissue autofluorescence, respectively. INL:
Inner nuclear layer. IPL: Inner plexiform layer. ONL: Outer nuclear layer. OPL: Outer plexiform layer.
PHL: Photoreceptor layer. RGC: Retinal ganglion cells. +/+: wild-type; -/-: guca1c KO. The images
are representative of the results observed in two fishes of each genotype. Two tissue sections per eye
were analyzed.
4. Discussion
In this study we have identified GUCA1C LoF as the likely genetic alteration underlying PCG in only
one out of 26 families of our cohort. Given the absence of the disease in previous generations of the family,
the presence of an affected brother/sister pair, and the presence of one non-affected sibling, we assumed a
recessive disease inheritance as the most probable cause of the disease. In addition, these features made
unlikely the existence of disease-associated de novo variants. Whole-exome sequencing revealed the
presence of one homozygous nonsense GUCA1C variant in the two affected siblings that segregated
with the disease following the expected autosomal recessive inheritance. We also applied filters to
identity rare compound heterozygous variants carried by the two affected siblings, with a high and
moderate predicted functional effect, but we did not identify any variant of this type. The GUANYLATE
CYCLASE ACTIVATOR 1C (GUCA1C) gene encodes the guanylate cyclase 3 activating protein (GCAP3),
a calcium-binding protein that belongs to the calmodulin gene superfamily [33]. This protein is composed
of 209 amino acids (23.8 kD) and presents 57% and 49% amino acid similarity with GCAP1 and GCAP2,
respectively. Like other GUCAs, GCAP3 contains a putative N-myristoylation site at Gly 2 and three
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putative EF-hand motifs involved in Ca(2+) binding [33]. Guanylate cyclase-activating proteins are
present in human photoreceptors and retinal ganglion cells [34], and in general, act as regulators of
photoreceptor guanylate cyclases playing a role in phototransduction [35]. It has also been found that
guanylate cyclase activators increase the rate of aqueous humor outflow leading to IOP reduction [26]
through cGMP-dependent regulation of Schlemm’s canal cell volume and TM cell volume [27]. Because of
this property, guanylate cyclase activators have been proposed as therapeutic agents for glaucoma [26,27].
In addition, it has been reported that a KO mouse for the α-1 subunit of soluble guanylate cyclase
developed glaucoma [36]. Based on these data, we hypothesize that the loss of GUCA1C function could
result in decreased cGMP, increased IOP, and glaucoma. In accordance with these ideas, the nonsense
homozygous GUCA1C variant (p.(Glu18Ter)) identified in the two siblings affected with PCG, may disrupt
cGMP synthesis, resulting in IOP elevation and glaucoma. To the best of our knowledge, no genetic
GUCA1C-associated disease has been identified; however, the alteration of other related genes, such as
GUCA1A, produces dominant cone or rod and cone dystrophies due to gain-of-function alleles that result
in a constitutively active protein [37,38]. The pathogenicity of the nucleotide substitution identified in
this family (c.52G > T) is supported by the predicted premature termination codon (PTC) generated
in the so-called “NMD boundary” of the mutant mRNA, located 50–55 bases 5′ of the last exon-exon
junction [39]. This likely leads to the complete LoF of the mutant GUCA1C gene product through
mRNA degradation by nonsense-mediated decay (NMD) [40]. PTCs are often associated with severe
phenotypes, and PTC-associated diseases account for approximately 11% of all genetic lesions causing
genetic diseases [41]. The overall reported frequency of this variant in gnomAD v2.1.1 is below 0.5%
with three homozygous genotypes, two of them correspond to cases while the third one corresponds
to one control. This finding may indicate the existence of incomplete penetrance in these subjects due
to functional compensation by paralogous genes such as GUCA1A, GUCA1B, or other functionally
related genes. Additionally, very limited phenotypic information is available for these subjects; therefore,
we cannot completely rule out the idea that at least some of them present with glaucoma. Identification of
GUCA1C LoF in only one out of 26 PCG cases indicates that this gene may contribute to PCG in a small
proportion of cases, which provides further support for the notion of elevated genetic heterogeneity in
this disease. Alternatively, and although we believe it highly unlikely, the possibility that this variant
is unrelated to the disease cannot be completely ruled out. Thus, further studies are required to firmly
establish its pathogenicity. The presence of GCAP3 in glaucoma-related human ocular tissues also
supports the idea that functional disruption of GUCA1C plays a role in this disease. In fact, to the best
of our knowledge, we report for the first time the presence of this protein in aqueous humor inflow
tissues, suggesting that functional alteration of GUCA1C may disrupt the balance between AH production
and drainage, resulting in elevated IOP and glaucoma. In adult retinal tissue, GCAP3 was detected
both in rod and cone photoreceptors according to its role in phototransduction. Previous studies have
detected GCPA3 only in cone photoreceptor cells, probably due to limitations of the technique [32].
In addition, our results showed GCAP3 immunoreactivity in the ganglion cell layer. In line with this data,
GCAP2 immnuoreactivity has also been reported in the human retina [34]. Overall, these data suggest
that functional disruption of GUCA1C might also cause direct retinal damage, but this hypothesis could
not be clinically evaluated in our study because the advanced disease in the patient who carried the LoF
variant in this gene.
In an additional effort to evaluate the pathogenicity of GUCA1C LoF in glaucoma and retinal
function, we analyzed the expression of this protein in the zebrafish eye and generated a guca1c
KO zebrafish line using CRIPS/Cas9 genome editing. In accordance with the expression in human
ocular tissues, GCAP3 was detected in aqueous humor inflow tissues (i.e., the non-pigmented
epithelium of the ciliary zone), photoreceptors and ganglion cells. In line with these results, it has
been reported that the gene is expressed mainly in human and zebrafish retinal cones [32]. qRT-PCR,
Western blot, and immunohistochemical analyses supported the LoF in the zebrafish line, though,
no gross macroscopic alterations were observed in adult KO animals. Histology analyses revealed
thinning of the corneal epithelium with an apparently unaltered corneal stroma, indicating that guca1c
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is required for the normal structure of the cornea. One of the most interesting phenotypic findings in
guca1c KO animals was the upregulation of GFAP in Müller cells, and the evidence of apoptosis in
some ganglion, indicating the existence of gliosis and glaucoma-like alterations associated with GCAP3
LoF. Increase of the GFAP intermediate filament protein is a universal early cellular marker for retinal
injury [42]. Although it is difficult to determine the cause of Müller cell activation in these knockout
animals, we can speculate that it might be a cellular response triggered by deficient expression of
GCAP3 in the retina. We could not assess whether retinal ganglion cell death was secondary to IOP
elevation or direct ganglion cell damage; and we only analyzed ganglion cell apoptosis in adult animals,
therefore, we could not determine the onset time and progression of these alterations. Moreover,
the low number of TUNEL positive cells observed may indicate that ganglion cell apoptosis was
not generalized in the retina at the time of the study. Additional biochemical, histological and time
course analysis are required to elicit the cause, onset time and extension of ganglion cell apoptosis and
retinal damage. We are aware that the paralog gene guca1d, and/or other functionally related genes,
might compensate, at least partially, guca1c LoF. Therefore, further studies are required to elucidate the
pathogenic and phenotypic effect of guca1c disruption.
5. Conclusions
Our results provide evidence for the role of GUCA1C as a novel candidate gene in PCG and offer
new insights into the role that this gene plays in the anterior segment and the retina.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/5/550/s1,
Figure S1: Negative controls used for the fluorescence immunohistochemistry detection of GCAP3 in human
ocular tissues shown in Figure 2. Figure S2: Retinal and corneal histology of adult (2 years) guca1c KO zebrafish.
Tissue Sections (10 µm) of wild-type (+/+) or guca1c KO (-/-) zebrafish eyes were stained with toluidine blue;
(A) and (B) Retina sections of wild-type and KO animals, respectively; (C) and (D) Cornea sections of wild-type
and KO animals, respectively. CE: Corneal epithelium.
Author Contributions: Conceptualization, J.E.; Methodology, S.M.-C., J.-D.A.-A., J.-J.F.-F., S.A.-M., R.A.-A.,
J.-M.B.-F., C.-D.M., L.M., N.C., L.F.-S., J.-M.M.-d.-l.-C., J.G.-F.; Investigation, S.M.-C., J.-D.A.-A., J.-J.F.-F.,
S.A.-M., R.A.-A., J.-M.B.-F., C.-D.M., L.M., N.C., L.F.-S., M.C.-P., J.-M.M.-d.-l.-C., J.G.-F. and J.E.; Resources,
J.E.; Writing—Original Draft Preparation, J.E.; Writing—Review & Editing, S.M.-C., J.-D.A.-A., J.-J.F.-F., S.A.-M.,
R.A.-A., J.-M.B.-F., C.-D.M., L.M., N.C., L.F.-S., M.C.-P., J.-M.M.-d.-l.-C., J.G.-F.; Visualization, S.M.-C. and J.E.;
Supervision, J.E.; Project Administration, J.E.; Funding Acquisition, J.E. and J.G.-F. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was funded by research grants from the “Instituto de Salud Carlos III/European Regional
Development Fund (ERDF)” (PI15/01193, PI19/00208 and RD16/0008/0019, OFTARED), the Regional Ministry
of Science and Technology of the Board of the Communities of “Castilla-La Mancha” (SBPLY/17/180501/000404;
http://www.educa.jccm.es/idiuniv/es). SA-M was sponsored by the Regional Ministry of Science and Technology
of the Board of the Communities of “Castilla-La Mancha” (PREJCCM2016/28).
Acknowledgments: We are grateful to the participating family. We would like to thank María-José Cabañero for
excellent technical assistance.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Chan, T.C.P.; Brookes, J.; Cavuoto, K.; Bitrian, E.; Grajewski, A.L. Primary congenital glaucoma and juvenile
open-angle glaucoma. In Childhood Glaucoma; Weinreb, R.N., Grajewski, A.L., Papadopoulos, M., Grigg, J.,
Freedman, S., Eds.; Kluger Publications: Ámsterdam, The Netherlands, 2013; pp. 137–153.
2. Francois, J. Congenital glaucoma and its inheritance. Ophthalmologica 1980, 181, 61–73. [CrossRef]
3. Gencik, A. Epidemiology and genetics of primary congenital glaucoma in Slovakia. Description of a form of
primary congenital glaucoma in gypsies with autosomal-recessive inheritance and complete penetrance.
Dev. Ophthalmol. 1989, 16, 76–115.
4. Elder, M.J. Congenital glaucoma in the West Bank and Gaza Strip. Br. J. Ophthalmol. 1993, 77, 413–416.
[CrossRef] [PubMed]
Genes 2020, 11, 550 16 of 18
5. Sarfarazi, M.; Stoilov, I. Molecular genetics of primary congenital glaucoma. Eye 2000, 14 Pt 3B, 422–428.
[CrossRef]
6. Weisschuh, N.; Wolf, C.; Wissinger, B.; Gramer, E. A clinical and molecular genetic study of German patients
with primary congenital glaucoma. Am. J. Ophthalmol. 2009, 147, 744–753. [CrossRef] [PubMed]
7. Colomb, E.; Kaplan, J.; Garchon, H.J. Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with
primary congenital glaucoma in France. Hum. Mutat. 2003, 22, 496. [CrossRef] [PubMed]
8. Campos-Mollo, E.; Lopez-Garrido, M.-P.; Blanco-Marchite, C.; Garcia-Feijoo, J.; Peralta, J.;
Belmonte-Martinez, J.; Ayuso, C.; Escribano, J. CYP1B1 mutations in Spanish patients with primary
congenital glaucoma: Phenotypic and functional variability. Mol. Vis. 2009, 15, 417–431. [PubMed]
9. López-Garrido, M.-P.; Medina-Trillo, C.; Morales-Fernandez, L.; Garcia-Feijoo, J.; Martínez-De-La-Casa, J.-M.;
García-Antón, M.; Escribano, J. Null CYP1B1 genotypes in primary congenital and nondominant juvenile
glaucoma. Ophthalmology 2013, 120, 716–723. [CrossRef]
10. Ali, M.; McKibbin, M.; Booth, A.; Parry, D.A.; Jain, P.; Riazuddin, S.A.; Hejtmancik, J.F.; Khan, S.N.; Firasat, S.;
Shires, M.; et al. Null mutations in LTBP2 cause primary congenital glaucoma. Am. J. Hum. Genet. 2009, 84,
664–671. [CrossRef]
11. Narooie-Nejad, M.; Paylakhi, S.H.; Shojaee, S.; Fazlali, Z.; Rezaei, K.M.; Nilforushan, N.; Yazdani, S.;
Babrzadeh, F.; Suri, F.; Ronaghi, M.; et al. Loss of function mutations in the gene encoding latent transforming
growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. Hum. Mol. Genet. 2009, 18,
3969–3977. [CrossRef]
12. Azmanov, D.N.; Dimitrova, S.; Florez, L.; Cherninkova, S.; Draganov, D.; Morar, B.; Saat, R.; Juan, M.;
Arostegui, J.I.; Ganguly, S.; et al. LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the
Roma/Gypsy founder population. Eur. J. Hum. Genet. 2011, 19, 326–333. [CrossRef] [PubMed]
13. Souma, T.; Tompson, S.W.; Thomson, B.R.; Siggs, O.M.; Kizhatil, K.; Yamaguchi, S.; Feng, L.; Limviphuvadh, V.;
Whisenhunt, K.N.; Maurer-Stroh, S.; et al. Angiopoietin receptor TEK mutations underlie primary congenital
glaucoma with variable expressivity. J. Clin. Investig. 2016, 126, 2575–2587. [CrossRef] [PubMed]
14. Ferre-Fernández, J.J.; Aroca-Aguilar, J.D.; Medina-Trillo, C.; Bonet-Fernández, J.M.; Méndez-Hernández, C.D.;
Morales-Fernández, L.; Corton, M.; Cabañero-Valera, M.J.; Gut, M.; Tonda, R.; et al. Whole-Exome Sequencing
of Congenital Glaucoma Patients Reveals Hypermorphic Variants in GPATCH3, a New Gene Involved in
Ocular and Craniofacial Development. Sci. Rep. 2017, 7, 46175. [CrossRef] [PubMed]
15. Kaur, K.; Reddy, A.B.; Mukhopadhyay, A.; Mandal, A.K.; Hasnain, S.E.; Ray, K.; Thomas, R.; Balasubramanian, D.;
Chakrabarti, S. Myocilin gene implicated in primary congenital glaucoma. Clin. Genet. 2005, 67, 335–340.
[CrossRef]
16. Vincent, A.L.; Billingsley, G.; Buys, Y.; Levin, A.V.; Priston, M.; Trope, G.; Williams-Lyn, D.; Heon, E.
Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. Am. J. Hum. Genet. 2002,
70, 448–460. [CrossRef]
17. Medina-Trillo, C.; Sánchez-Sánchez, F.; Aroca-Aguilar, J.D.; Ferre-Fernández, J.J.; Morales, L.;
Méndez-Hernández, C.D.; Blanco-Kelly, F.; Ayuso, C.; García-Feijoo, J.; Escribano, J. Hypo- and hypermorphic
FOXC1 mutations in dominant glaucoma: Transactivation and phenotypic variability. PLoS ONE 2015,
10, e0119272. [CrossRef]
18. Medina-Trillo, C.; Aroca-Aguilar, J.-D.; Mendez-Hernandez, C.-D.; Morales, L.; Garcia-Anton, M.; Garcia-Feijoo, J.;
Escribano, J. Rare FOXC1 variants in congenital glaucoma: Identification of translation regulatory sequences.
Eur. J. Hum. Genet. 2016, 24, 672–680. [CrossRef]
19. Siggs, O.M.; Souzeau, E.; Taranath, D.A.; Dubowsky, A.; Chappell, A.; Zhou, T.; Javadiyan, S.; Nicholl, J.;
Kearns, L.S.; Staffieri, S.E.; et al. Biallelic CPAMD8 Variants Are a Frequent Cause of Childhood and Juvenile
Open-Angle Glaucoma. Ophthalmology 2020. [CrossRef]
20. Bonet-Fernández, J.M.; Aroca-Aguilar, J.D.; Corton, M.; Ramírez, A.I.; Alexandre-Moreno, S.; García-Antón, M.T.;
Salazar, J.J.; Ferre-Fernández, J.J.; Atienzar-Aroca, R.; Villaverde, C.; et al. CPAMD8 loss-of-function underlies
non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular
matrix. Hum. Genet. 2020. [CrossRef]
Genes 2020, 11, 550 17 of 18
21. Ortego, J.; Escribano, J.; Becerra, S.; CocaPrados, M. Gene expression of the neurotrophic pigment
epithelium-derived factor in the human ciliary epithelium—Synthesis and secretion into the aqueous
humor. Investig. Ophthalmol. Vis. Sci. 1996, 37, 2759–2767.
22. Westerfield, M. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio), 5th ed.; University of
Oregon Press: Eugene, OR, USA, 2000; p. 300.
23. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
24. Aroca-Aguilar, J.-D.; Martinez-Redondo, F.; Martin-Gil, A.; Pintor, J.; Coca-Prados, M.; Escribano, J.
Bicarbonate-Dependent Secretion and Proteolytic Processing of Recombinant Myocilin. PLoS ONE 2013,
8, e54385. [CrossRef] [PubMed]
25. Meeker, N.D.; Hutchinson, S.A.; Ho, L.; Trede, N.S. Method for isolation of PCR-ready genomic DNA from
zebrafish tissues. Biotechniques 2007, 43, 610, 612, 614. [CrossRef] [PubMed]
26. Ellis, D.Z. Guanylate cyclase activators, cell volume changes and IOP reduction. Cell Physiol. Biochem. 2011,
28, 1145–1154. [CrossRef]
27. Buys, E.S.; Potter, L.R.; Pasquale, L.R.; Ksander, B.R. Regulation of intraocular pressure by soluble and
membrane guanylate cyclases and their role in glaucoma. Front. Mol. Neurosci. 2014, 7, 38. [CrossRef]
28. Imanishi, Y.; Yang, L.; Sokal, I.; Filipek, S.; Palczewski, K.; Baehr, W. Diversity of guanylate cyclase-activating
proteins (GCAPs) in teleost fish: Characterization of three novel GCAPs (GCAP4, GCAP5, GCAP7) from
zebrafish (Danio rerio) and prediction of eight GCAPs (GCAP1-8) in pufferfish (Fugu rubripes). J. Mol. Evol.
2004, 59, 204–217. [CrossRef]
29. Rätscho, N.; Scholten, A.; Koch, K.W. Expression profiles of three novel sensory guanylate cyclases and
guanylate cyclase-activating proteins in the zebrafish retina. Biochim. Biophys. Acta 2009, 1793, 1110–1114.
[CrossRef]
30. Fries, R.; Scholten, A.; Säftel, W.; Koch, K.W. Zebrafish guanylate cyclase type 3 signaling in cone
photoreceptors. PLoS ONE 2013, 8, e69656. [CrossRef]
31. Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: Improving the sensitivity of progressive multiple
sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res. 1994, 22, 4673–4680. [CrossRef]
32. Imanishi, Y.; Li, N.; Sokal, I.; Sowa, M.E.; Lichtarge, O.; Wensel, T.G.; Saperstein, D.A.; Baehr, W.;
Palczewski, K. Characterization of retinal guanylate cyclase-activating protein 3 (GCAP3) from zebrafish to
man. Eur. J. Neurosci. 2002, 15, 63–78. [CrossRef]
33. Haeseleer, F.; Sokal, I.; Li, N.; Pettenati, M.; Rao, N.; Bronson, D.; Wechter, R.; Baehr, W.; Palczewski, K.
Molecular characterization of a third member of the guanylyl cyclase-activating protein subfamily.
J. Biol. Chem. 1999, 274, 6526–6535. [CrossRef] [PubMed]
34. Cuenca, N.; Lopez, S.; Howes, K.; Kolb, H. The localization of guanylyl cyclase-activating proteins in the
mammalian retina. Investig. Ophthalmol. Vis. Sci. 1998, 39, 1243–1250.
35. Palczewski, K.; Sokal, I.; Baehr, W. Guanylate cyclase-activating proteins: Structure, function, and diversity.
Biochem. Biophys. Res. Commun. 2004, 322, 1123–1130. [CrossRef] [PubMed]
36. Buys, E.S.; Ko, Y.C.; Alt, C.; Hayton, S.R.; Jones, A.; Tainsh, L.T.; Ren, R.; Giani, A.; Clerte’, M.; Abernathy, E.; et al.
Soluble Guanylate Cyclase a1-Deficient Mice: A novel murine model for Primary Open Angle Glaucoma.
Ann. Neurosci. 2013, 20, 65–66. [CrossRef]
37. Buch, P.K.; Mihelec, M.; Cottrill, P.; Wilkie, S.E.; Pearson, R.A.; Duran, Y.; West, E.L.; Michaelides, M.;
Ali, R.R.; Hunt, D.M. Dominant cone-rod dystrophy: A mouse model generated by gene targeting of the
GCAP1/Guca1a gene. PLoS ONE 2011, 6, e18089. [CrossRef]
38. Michaelides, M.; Wilkie, S.E.; Jenkins, S.; Holder, G.E.; Hunt, D.M.; Moore, A.T.; Webster, A.R. Mutation in
the gene GUCA1A, encoding guanylate cyclase-activating protein 1, causes cone, cone-rod, and macular
dystrophy. Ophthalmology 2005, 112, 1442–1447. [CrossRef]
39. Nagy, E.; Maquat, L.E. A rule for termination-codon position within intron-containing genes: When nonsense
affects RNA abundance. Trends Biochem. Sci. 1998, 23, 198–199. [CrossRef]
Genes 2020, 11, 550 18 of 18
40. Brogna, S.; Wen, J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol. 2009, 16,
107–113. [CrossRef]
41. Mort, M.; Ivanov, D.; Cooper, D.N.; Chuzhanova, N.A. A meta-analysis of nonsense mutations causing
human genetic disease. Hum. Mutat. 2008, 29, 1037–1047. [CrossRef]
42. Bringmann, A.; Pannicke, T.; Grosche, J.; Francke, M.; Wiedemann, P.; Skatchkov, S.N.; Osborne, N.N.;
Reichenbach, A. Müller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 2006, 25, 397–424.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
